In vivo studies showed that bevacizumab inhibits both proliferation and migration of endothelial cells induced by VEGF‐A; besides in some models of human BC, the treatment with bevacizumab was associated to a reduction in microvascular density 5. This evidence concerns the gene VEGFA and breast cancer.